Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + gemcitabine/cisplatin with or without trilaciclib in unresectable or metastatic urothelial carcinoma
ChiCTR2400087886Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of tislelizumab in transitional cell carcinoma (TCC) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Progression-free survival and Incidence of Grade 3/4 neutropenia. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2400087886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087886.